{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-022881","form_type":"8-K","ticker":"CING","cik":"0001862150","company_name":"Cingulate Inc.","filed_at":"2026-05-14T12:10:16+00:00","discovered_at":"2026-05-14T12:15:00.286353+00:00","generated_at":"2026-05-14T12:16:00.402724+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cingulate Q1 net loss widens to $9.3M; cash at $25.9M; CTx-1301 PDUFA May 31","bullets":["Net loss of $9.3M for Q1 2026, up from $3.9M a year ago; G&A expenses surged to $5.7M on commercial build-out.","Cash and cash equivalents $25.9M at Mar 31, up $14.9M from Dec 31, extending runway into 2027.","FDA review of CTx-1301 NDA ongoing; PDUFA target action date remains May 31, 2026.","Commercial readiness advanced with AI-driven tools and IQVIA sales force agreement for potential launch.","R&D expenses decreased 1.8% to $2.2M as clinical studies concluded, partly offset by regulatory and CMC activities."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-022881","json":"https://secwatch.observer/filing/0001493152-26-022881.json","markdown":"https://secwatch.observer/filing/0001493152-26-022881.md","text":"https://secwatch.observer/filing/0001493152-26-022881.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000149315226022881/0001493152-26-022881-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000149315226022881/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T12:16:00.402724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5acdfd031b7c68f3a7b811b8effcf82c53973008","claim":"Cingulate Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $9.3 million for the three months ended March 31, 2026.","evidence_excerpt":"Cingulate Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026 and providing a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1862150/000149315226022881/0001493152-26-022881-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Net income","value":"Net loss was $9.3 million for the three months ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}